NCT03429868

PET and MRI in Prognosis Prediction of NPC

Completed NA Last updated 10 May 2023

What this trial tests

NA trial testing integrated PET/MRI in Nasopharyngeal Carcinoma in 180 participants. Completed in 31 July 2020.

Timeline

1 August 2015

Primary endpoint
31 July 2020

31 July 2020

Quick facts

Lead sponsor	Chang Gung Memorial Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	180
Start date	1 August 2015
Primary completion	31 July 2020
Estimated completion	31 July 2020
Sites	1 location across Taiwan

Drugs / interventions tested

• integrated PET/MRI

Conditions studied

• Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Chang Gung Memorial Hospital

Who can join

20 and older, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nasopharyngeal carcinoma (NPC) differs from other head and neck malignancies terms of its epidemiology, pathology, and treatment outcome. Integrated PET/MRI is a new imaging modality, which can simultaneously acquire PET and MRI images. Considering the lack of reports on the use of hybrid PET/MRI systems in prognosis prediction in NPC, the investigators conduct this prospective study to investigate the roles of integrated PET/MRI parameters for predicting treatment outcome and prognosis in patients with NPC.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Prognostic utility of <sup>18</sup>F-FDG PET/MRI with intravoxel incoherent motion imaging in nasopharyngeal carcinoma.
   Chan SC, Ng SH, Yeh CH, Lin YC, et al · · 2025 · cited 2× · PMID 40601020 · DOI 10.1007/s00259-025-07425-6